

NERVIANO MEDICAL SCIENCES

Nerviano Medical Sciences (NMS) China Joins Roche Accelerator to Advance Oncology Innovation

Nerviano (Milan), Italy – Shanghai, China 17 November 2025 — Nerviano Medical Sciences (NMS), a clinical-stage biopharmaceutical company focused on oncology innovation, today announced that its subsidiary, Nerviano Medical Sciences (Shanghai) Co., Ltd. (NMS China), has officially joined the Roche Accelerator.

NMS China is part of the Roche Accelerator since October 2025. The **Roche Accelerator** is **Roche's first in-house accelerator globally, representing Roche's long-term commitment to Shanghai and China.** The Roche Accelerator aims to catalyze and empower scientists and entrepreneurs to accelerate breakthrough innovation into next-generation therapeutics.

Joining the Roche Accelerator marks a new milestone for NMS China, reinforcing the company's mission to bring differentiated cancer therapies to patients through scientific excellence and global partnerships.

Entrectinib, a precision oncology therapy approved for the treatment of NTRK and ROS1 fusion-positive cancers, **originated from NMS** and was **out-licensed to Ignyta, subsequently acquired by Roche.** This success story exemplifies NMS's commitment to advancing transformative therapies from discovery to global reach.

*"We are delighted to see Nerviano Medical Sciences join the Roche Accelerator," said **Hugues Dolgos, Pharm.D, CEO of NMS Group and NMS Srl.** "By bringing together Roche's global innovation ecosystem and NMS's deep oncology expertise, we aim to accelerate the translation of breakthrough science into impactful therapies for patients in China and around the world."*

*"Becoming part of Roche Accelerator is a significant step for NMS China," said **Li Dadong, Ph.D., CEO of NMS China.** "This partnership provides us with an invaluable environment to collaborate, innovate, and accelerate the development of our precision oncology programs."*

NMS will continue to expand its research and development in oncology, focusing on targeted therapies, antibody–drug conjugates (ADCs), and mechanism-driven approaches to cancer treatment.

About Nerviano Medical Sciences

[Nerviano Medical Sciences S.r.l.](https://www.nervianoms.com) focuses on discovering and clinically developing small molecule NCEs for oncology, aiming to deliver first- and best-in-class personalized cancer treatments through innovative mechanisms and novel drug targets. Our pipeline, built from our validated kinase platform, includes projects from early preclinical to clinical stages, advanced both internally and in partnership.

NERVIANO MEDICAL SCIENCES

NMS Srl combines biotech agility with big pharma quality, guided by an experienced management team and a skilled staff with global expertise in research, drug discovery, and clinical development. A core strength lies in our renowned kinase inhibitor platform, featuring an extensive chemical library and IP coverage, which has led to successful out-licensing deals, including encorafenib and entrectinib. Additionally, we are advancing a PARP-family-focused platform to discover NCEs targeting NAD-binding pockets, with potential expansion to other NAD-dependent enzymes. Our growing payload-linker platform further enhances our pipeline by enabling next-generation ADC production.

Collaborating globally with academic, clinical, and industry partners, we seek further strategic alliances to develop, commercialize, and expand our product portfolio while exploring in-licensing opportunities for promising clinical assets

For more information, visit <https://www.nervianoms.com>.

Media Relations: mediarelations@nervianoms.com